It is unclear from these data why MMR mutation had no significant effect on survival in patients with IDH-wild-type glioblastoma, although this may be due in part to the fact that IDH-wild-type glioblastoma patients have such a dismal prognosis that there is not much capacity for MMR mutation to worsen the outcome. The gene discussed is IDH2; the disease is glioblastoma.